---
id: 6c3b228f-a6e4-4961-9e66-4640510323f2
---



[[Omnivore MOC]] | [Read on Omnivore](https://omnivore.app/me/current-advances-and-challenges-in-car-t-cell-therapy-for-solid--18adc03d1f0) | [Read Original](https://ehoonline.biomedcentral.com/articles/10.1186/s40164-023-00373-7/tables/1)


# Note
clinical trials of CAR T cell target to solid tumor



# Full Contetns
| Antigen                                    | Items | Conditions or disease                                                                                                                                                                                                                                                                                                                                                                                                                            | Intervention/treatments                                                                                                                                                                                                                                                                                                                                    | Phase      | NCT number                                                                                                                                                                                                                  |
| ------------------------------------------ | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| MSLN                                       | 17    | Colorectal Cancer, Ovarian Cancer, Advanced Solid Tumor, Mesothelioma, Metastatic Liver Cancer, Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer, Gut Microbiota                                                                                                                                                                                                                                                    | αPD1-MSLN-CAR T cells; CTLA-4/PD-1 antibodies expressing mesoCAR-T; Mesothelin-directed CAR T cells; RD133; Fludarabine; Aldesleukin                                                                                                                                                                                                                       | I, II      | NCT04503980, NCT05089266, NCT03182803, NCT04489862, NCT03747965, NCT03545815, NCT03030001, NCT03615313, NCT05166070, NCT01583686, NCT02930993, NCT04981691, NCT03323944, NCT05373147, NCT05141253, NCT05344976, NCT03941626 |
| B7H3 (CD276)                               | 9     | Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer                                                                                                                                                            | Second generation 4-1BBζ B7H3-EGFRt-DHFR (selected) and a second generation 4-1BBζ CD19-Her2tG; Targeting CD276 autologous chimeric antigen receptor T cells; Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells; EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer; Fludarabine, Cyclophosphamide | I, II      | NCT04483778, NCT04691713, NCT04897321, NCT04864821, NCT05211557, NCT05323201, NCT04670068, NCT05515185, NCT05190185                                                                                                         |
| EGFR                                       | 8     | PD-1 Antibody, CAR-T Cells, Advanced Solid Tumor, Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Advanced Solid Tumor, PD-1 Antibody, CAR-T Cells, Advanced Malignancies, Solid Tumor, Adult, EGFR Overexpression, Non Small Cell Lung Cancer, Biological: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells      | HerinCAR-PD1 cells; second generation 4-1BB#, EGFR806-EGFRt, second generation 4-1BB#, EGFR806-EGFRt and a second generation 4 1BB# CD19-Her2Tg; anti-CTLA-4/PD-1 expressing EGFR-CAR-T; HerinCAR-PD1 cells; EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer                                          | I, II      | NCT02862028, NCT03618381, NCT03182816, NCT02873390, NCT04976218, NCT04153799, NCT05060796, NCT01218867                                                                                                                      |
| GD2                                        | 7     | Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors, Osteosarcoma, Ewing Sarcoma, Sarcoma, Melanoma, GD2 Positive Glioma, CAR-T Cell Immunotherapy                                                                                                                                                                                                                                                                                 | GD2-CART01; Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide; CAR-T cell Immunotherapy; iC9-GD2 T Cells – frozen, iC9-GD2 T Cells – fresh, Cytoxan, Fludara, Keytruda, iC9-GD2 T cells; 4SCAR-GD2; iC9.GD2.CAR.IL-15 T cells, Cyclophosphamide, Fludarabine;                                                                                      | I, II      | NCT03373097, NCT02107963, NCT03252171, NCT01822652, NCT02992210; NCT03721068, NCT03635632                                                                                                                                   |
| HER2                                       | 6     | Gastric Cancer, Breast Cancer, Ovarian Cancer, Sarcoma, Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Glioma, Bile Duct Cancer, Biliary Tract Cancer, Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant, Sarcoma                                                                                                 | CAR T cell therapy; CCT303-406; CAdVEC; Anti-HER2 CAR-T; CT-0508; Dual-targeting HER2 and PD-L1 CAR-T cells; cells; Pembrolizumab Injectable Product, Nivolumab Injectable Product, Lymphodepletion Chemotherapy                                                                                                                                           | I, II      | NCT04650451, NCT04511871, NCT03740256, NCT02713984, NCT04660929, NCT04684459, NCT04995003                                                                                                                                   |
| MUC1                                       | 7     | Advanced Solid Tumor, Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Malignant Glioma of Brain, Advanced Esophageal Cancer | Anti-CTLA-4/PD-1 expressing MUC1-CAR-T; P-MUC1C-ALLO1 CAR-T cells, Rimiducid, CART-TnMUC1, Cyclophosphamide, Fludarabine, anti-MUC1 CAR-pNK cells                                                                                                                                                                                                          | I, II      | NCT03179007, NCT02587689, NCT05239143, NCT04025216, NCT02839954, NCT03706326, NCT02617134                                                                                                                                   |
| NKG2D                                      | 6     | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma Prostate Cancer, Gastric Cancer, Glioma, Malignancy, Refractory Cancer, Relapsed Cancer, CRC                                                                                                                                                                                          | NKG2D-based CAR T-cells; Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell; KD-025 CAR-T cells                                                                                                                                                                                                              | I          | NCT05131763, NCT04270461, NCT04107142, NCT05302037, NCT05382377, NCT04550663                                                                                                                                                |
| CEA                                        | 6     | Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Metastatic Tumor, Recurrent Cancer                                                                                                                                                                                                                                                                            | CEA CAR-T cells, Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR + FU/FA, Capecitabine                                                                                                                                                                                                                                                              | I, II, III | NCT04348643, NCT03818165, NCT04037241, NCT05396300, NCT05415475, NCT05240950                                                                                                                                                |
| EpCAM                                      | 2     | Advanced Solid Tumor, Neoplasms, Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent, Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer, Gastric Cancer, Hepatic Carcinoma                                                                                                                                                                                                        | TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy; CAR-T cells recognizing EpCAM                                                                                                                                                                                                                                                         | I, II      |                                                                                                                                                                                                                             |
| Nectin4/FAP                                | 1     | Nectin4-positive Advanced Malignant Solid Tumor                                                                                                                                                                                                                                                                                                                                                                                                  | Biological: CAR-T therapy for nectin4-positive malignant solid tumor                                                                                                                                                                                                                                                                                       | I          | NCT03932565                                                                                                                                                                                                                 |
| LOH                                        | 1     | Solid Tumor, Adult Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer                                                                                                                                                                                                                                                                                                                                 | Other: Leukapheresis, Diagnostic Test: Next Generation Sequencing (NGS), Diagnostic Test: Long Range NGS HLA typing                                                                                                                                                                                                                                        | NA         |                                                                                                                                                                                                                             |
| CD22                                       | 1     | Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC                                                                                                                                                                                                                                                                                                                                                                                              | Biological: Autologous aPD-L1 armored anti-CD22 CAR T cells                                                                                                                                                                                                                                                                                                | I          | NCT04556669                                                                                                                                                                                                                 |
| Claudin18.2                                | 8     | Advanced Solid Tumor, Gastric Cancer, Pancreatic Ductal Adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                           | Drug: CAR-CLDN18.2 T-Cells, Drug: PD-1 Monoclonal Antibody, Drug: Chemotherapy, Drug: Cell injection, Drug: IBI345                                                                                                                                                                                                                                         | I          | NCT03874897, NCT05284968, NCT03890198, NCT04467853, NCT05472857, NCT05393986, NCT05199519, NCT04966143                                                                                                                      |
| CLDN6                                      | 1     | Solid Tumor                                                                                                                                                                                                                                                                                                                                                                                                                                      | Biological: CLDN6 CAR-T, Biological: CLDN6 RNA-LPX                                                                                                                                                                                                                                                                                                         | I,II       | NCT04503278                                                                                                                                                                                                                 |
| LeY                                        | 1     | Advanced Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                  | Biological: LeY CAR T cells                                                                                                                                                                                                                                                                                                                                | I          | NCT03851146                                                                                                                                                                                                                 |
| Glypican 3                                 | 5     | Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor                                                                                                                                                                                                                                                                                                                                               | Genetic: AGAR T cells, Drug: Cytoxan, Genetic: CARE T cells, Drug: Cytoxan, Genetic: GAP T cells, Drug: Cytoxan, Drug: Fludara                                                                                                                                                                                                                             | I          | NCT04377932, NCT05103631, NCT04715191, NCT02932956, NCT04093648                                                                                                                                                             |
| PSCA                                       | 1     | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma                                                                                                                                                                                                                                                     | Biological: BPX-601, Drug: Rimiducid                                                                                                                                                                                                                                                                                                                       | I, II      | NCT02744287                                                                                                                                                                                                                 |
| ROR1                                       | 1     | Triple Negative Breast Cancer, TNBC-Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, Recurrent, and 5 more                                                                                                                                                                               | Biological: LYL797                                                                                                                                                                                                                                                                                                                                         | I          |                                                                                                                                                                                                                             |
| Treatment for CRS                          | 1     | Solid Tumor, Hematological Malignancy                                                                                                                                                                                                                                                                                                                                                                                                            | Drug: Metoprolol, Drug: metoprolol, infliximab, etanercept, tocilizumab and/or other agents                                                                                                                                                                                                                                                                | I, II      |                                                                                                                                                                                                                             |
| PSMA                                       | 4     | Bladder Cancer, Urothelial Carcinoma Bladder, Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site and 7 more                                                                                                                                                       | Genetic: 4SCAR-PSMA, Genetic: 4SCAR-Fra, P-PSMA-101 CAR-T cells, Drug: Rimiducid, Drug: Cyclophosphamide (Non-IMP), Drug: Fludarabine (Non-IMP), Drug: UniCAR02-T-pPSMA, Drug: UniCAR02-T (IMP)                                                                                                                                                            | I, II      | NCT03185468, NCT04249947, NCT04429451, NCT04633148                                                                                                                                                                          |
| Targeting Cervical cancer                  | 1     | Cervical Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                  | Biological: Cervical cancer-specific CAR-T cells                                                                                                                                                                                                                                                                                                           | I, II      | NCT03356795                                                                                                                                                                                                                 |
| Targeting Pancreatic Cancer                | 2     | Pancreatic Cancer, CAR Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian                                                                                                                                                                                                                                 | Drug: Chimeric antigen receptor T cell                                                                                                                                                                                                                                                                                                                     | I          |                                                                                                                                                                                                                             |
| PRGN-3005                                  | 1     | Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8 and 24 more                                                                                                                                                                                             | Biological: PRGN-3005 UltraCAR-T cells                                                                                                                                                                                                                                                                                                                     | I          | NCT03907527                                                                                                                                                                                                                 |
| IM96                                       | 1     | Advanced Solid Tumors, Digestive System Neoplasms, Pancreatic Cancer Resectable, Colorectal (Colon or Rectal) Cancer                                                                                                                                                                                                                                                                                                                             | Drug: IM96 CAR-T cells                                                                                                                                                                                                                                                                                                                                     | I          |                                                                                                                                                                                                                             |
| IM192                                      | 1     | Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer                                                                                                                                                                                                                                                                                                                                                        | Drug: IM92 CAR-T cells                                                                                                                                                                                                                                                                                                                                     | I          |                                                                                                                                                                                                                             |
| IL13Ralpha2                                | 1     | Clinical Stage IV Cutaneous Melanoma AJCC v8, IL13RA2 Positive, Metastatic Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV                                                                                                                                                                                                                                                                                                 | Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Drug: Recombinant Interleukin-2                                                                                                                                          | I          |                                                                                                                                                                                                                             |
| Targeting Sarcoma                          | 2     | Sarcoma, Osteoid Sarcoma, Ewing Sarcoma                                                                                                                                                                                                                                                                                                                                                                                                          | Biological: Sarcoma-specific CAR-T                                                                                                                                                                                                                                                                                                                         | I, II      | NCT03356782, NCT04433221                                                                                                                                                                                                    |
| GPC3                                       | 1     | Carcinoma, Hepatocellular                                                                                                                                                                                                                                                                                                                                                                                                                        | Drug: TAI-GPC3-CART cells                                                                                                                                                                                                                                                                                                                                  | I, II      | NCT02715362                                                                                                                                                                                                                 |
| Targeting Malignant Glioma                 | 1     | Glioma, Malignant Glioma of Brain, Recurrence Tumor                                                                                                                                                                                                                                                                                                                                                                                              | Biological: chimeric antigen receptor T cells                                                                                                                                                                                                                                                                                                              | I          | NCT03423992                                                                                                                                                                                                                 |
| MOv19-BBz                                  | 1     | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma                                                                                                                                                                                                                                                                                                                                                                              | Drug: MOv19-BBz CAR T cells, Device: Alpha Folate Receptor expression test                                                                                                                                                                                                                                                                                 | I          | NCT03585764                                                                                                                                                                                                                 |
| CT041                                      | 1     | Malignant Neoplasms of Digestive Organs                                                                                                                                                                                                                                                                                                                                                                                                          | Biological: gucy2c cart cells                                                                                                                                                                                                                                                                                                                              | I          |                                                                                                                                                                                                                             |
| Gucy2c                                     | 2     | Malignant Neoplasms of Digestive Organs                                                                                                                                                                                                                                                                                                                                                                                                          | Biological: gucy2c cart cells                                                                                                                                                                                                                                                                                                                              | I          |                                                                                                                                                                                                                             |
| TM4SF1/EpCAM                               | 1     | Advanced Solid Tumor, Neoplasms                                                                                                                                                                                                                                                                                                                                                                                                                  | Biological: TM4SF1- and EpCAM-positive CAR T-cell therapy                                                                                                                                                                                                                                                                                                  | NA         |                                                                                                                                                                                                                             |
| CD70                                       | 3     | Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer                                                                                                                                                                                                                                                                                                                                                      | Biological: CD70 CAR-T cells                                                                                                                                                                                                                                                                                                                               | I          | NCT05468190, NCT05518253, NCT05420545                                                                                                                                                                                       |
| GD2/PSMA                                   | 1     | Solid Tumor                                                                                                                                                                                                                                                                                                                                                                                                                                      | Biological: bi-4SCAR GD2/PSMA T cells                                                                                                                                                                                                                                                                                                                      | I, II      | NCT05437315                                                                                                                                                                                                                 |
| EGFR/B7H3                                  | 1     | EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer                                                                                                                                                                                                                                                                                                                                             | Biological: EGFR/B7H3 CAR-T                                                                                                                                                                                                                                                                                                                                | I          | NCT05341492                                                                                                                                                                                                                 |
| ROR2                                       | 1     | Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer                                                                                                                                                                                                                                                                                                                                                              | Biological: CCT301-59                                                                                                                                                                                                                                                                                                                                      | I          | NCT03960060                                                                                                                                                                                                                 |
| OX40                                       | 1     | Lung Cancer, Hepatocellular Carcinoma, Solid Tumor                                                                                                                                                                                                                                                                                                                                                                                               | Combination Product: CpG-ODN                                                                                                                                                                                                                                                                                                                               | I          | NCT04952272                                                                                                                                                                                                                 |
| HER2/PD-L1                                 | 1     | Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant                                                                                                                                                                                                                                                                                                                                                                                     | Biological: Dual-targeting HER2 and PD-L1 CAR-T cells                                                                                                                                                                                                                                                                                                      | I          | NCT04684459                                                                                                                                                                                                                 |
| VEGFR1/PD-L1                               | 1     | Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises                                                                                                                                                                                                                                                                                                                                                                     | Biological: Dual-targeting VEGFR1 and PD-L1 CAR-T cells                                                                                                                                                                                                                                                                                                    | I          | NCT05477927                                                                                                                                                                                                                 |
| Effects on PC by gut microbiota regulation | 1     | Pancreatic Cancer, Gut Microbiota, CAR-T                                                                                                                                                                                                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                                                                                                                                                         | NA         |                                                                                                                                                                                                                             |
| PD-L1                                      | 1     | Glioblastoma Multiforme                                                                                                                                                                                                                                                                                                                                                                                                                          | Biological: Anti-PD-L1 CSR T cells, Drug: Cyclophosphamide, Drug: Fludarabine                                                                                                                                                                                                                                                                              | I          | NCT02937844                                                                                                                                                                                                                 |
| CD44v6                                     | 1     | Cancers Which Are CD44v6 Positive                                                                                                                                                                                                                                                                                                                                                                                                                | Biological: CD44v6-specific CAR gene-engineered T cells                                                                                                                                                                                                                                                                                                    | I, II      | NCT04427449                                                                                                                                                                                                                 |
| EBV                                        | 1     | Nasopharyngeal Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                         | Biological: EBV-TCR-T (YT-E001) cells                                                                                                                                                                                                                                                                                                                      | II         | NCT03648697                                                                                                                                                                                                                 |
| NY-ESO-1                                   | 1     | Lung Cancer, Nonsmall Cell Recurrent                                                                                                                                                                                                                                                                                                                                                                                                             | Drug: Cyclophosphamide and Fludarabine, Biological: Anti-NY-ESO-1 TCR                                                                                                                                                                                                                                                                                      | I          |                                                                                                                                                                                                                             |
| GD2/CD70                                   | 1     | Cancer Disease                                                                                                                                                                                                                                                                                                                                                                                                                                   | Biological: bi-4SCAR GD2/CD70 T cells                                                                                                                                                                                                                                                                                                                      | I, II      | NCT05438368                                                                                                                                                                                                                 |
| MUC16ecto                                  | 1     | Solid Tumors                                                                                                                                                                                                                                                                                                                                                                                                                                     | Procedure: Production of Genetically-modified T cells, Drug: Cyclophosphamide, Device: IP Catheter Insertion, Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Drug: Fludarabine                                                                                                                                                  | I          | NCT02498912                                                                                                                                                                                                                 |

1. aThe clinical trials data was collected from clinicaltrials.gov. There were 125 studies clinical trials about CAR-T treatment for solid tumor in the clinicaltrials.gov as of September 07, 2022